Preadium Platform Propels European EHR Market into Research Era

The European Electronic Health Record (EHR) and Electronic Patient Record (EPR) market is entering a "research-ready era," driven by the increasing adoption of platforms that connect clinical researchers with real-world patient data. This transformation is facilitating the generation of real-world evidence (RWE) and accelerating patient recruitment for clinical trials across the continent. Preadium, a provider of clinical trials data platforms, reports its system is a key factor in this shift.

Advancing Clinical Research Data Access

Historically, accessing and utilizing patient data from digital records for clinical trials presented significant challenges due to fragmentation, privacy concerns, and technical barriers. Preadium's platform addresses these issues by offering a secure and efficient mechanism for extracting, anonymizing, and standardizing patient data for research. This capability allows researchers to identify eligible patients more quickly and gain deeper understanding of disease progression and treatment outcomes.

The system is currently deployed across 11 European countries, establishing connections with over 250 hospitals. This network provides access to data from more than 100 million patients, representing a substantial step forward in facilitating large-scale, multi-country clinical investigations. The platform supports various therapeutic areas, assisting pharmaceutical companies, academic institutions, and contract research organizations (CROs) in conducting more effective studies.

The shift towards a research-ready EHR/EPR market is also supported by evolving regulatory frameworks. European health authorities increasingly value real-world data to supplement traditional randomized controlled trials, particularly for understanding long-term safety and effectiveness. Preadium's platform adheres to stringent European data protection regulations, including GDPR, ensuring patient privacy and data security.

"The ability to securely and efficiently access real-world patient data from EHR/EPR systems is fundamentally changing how clinical trials are conducted in Europe."

— Dr. Lena Schmidt, Head of Clinical Research Partnerships at Preadium

Impact on Drug Development and Patient Outcomes

The market for EHR/EPR-driven research platforms is expected to continue its rapid expansion. As more hospitals adopt digital records and researchers increasingly demand real-world data, such platforms will become essential tools for medical advancements. This trend holds the promise of shortening drug development cycles and reducing research costs.

The increased availability of real-world evidence is becoming important for regulatory submissions and post-market surveillance. This advancement in data utilization is poised to bring new therapies to patients more quickly. Preadium remains focused on expanding its network and enhancing its platform capabilities to meet the evolving requirements of the European clinical research community.

The integration of patient data from diverse sources through systems like the Preadium platform represents a significant evolution for medical research. This development promises to accelerate the pace of scientific discovery and improve the quality of patient care across Europe. The focus on secure and compliant data access underpins this transformation, ensuring ethical standards are maintained as research capabilities expand.